Investors & Media
News Releases
Corporate News
- July 23, 2020Annovis Bio CEO Appears on Executive Leaders Radio Program
- July 20, 2020Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
- July 7, 2020Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
- June 16, 2020Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
- June 9, 2020Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
- June 2, 2020Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
- June 1, 2020Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
- May 27, 2020Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19
- May 1, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
- April 30, 2020Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients
Events & Presentations
-
Cantor Global Healthcare Conference – September 28, 2021 View Webcast
-
Annovis Presentation - November 2021
-
CTAD Presentation
-
CTAD Poster
-
New Parkinson’s Efficacy Data - October 5, 2021
-
Biomarkers for Alzheimer’s Disease Presentation
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top